Pfizer CEO Albert Bourla publicly denounced Robert F. Kennedy Jr.’s vaccine positions as “anti-science,” stressing that such viewpoints threaten public confidence in immunization programs. Speaking at a Wall Street Journal event during the World Economic Forum in Davos, Bourla highlighted that while he and Kennedy have engaged constructively on topics like cancer research and drug pricing, discussions collapse when vaccines are raised. He characterized Kennedy’s stance as ideological rather than evidence-based, warning that persistent misinformation could undermine uptake of lifesaving vaccines and stall progress on pandemic preparedness.

In his Davos remarks, Bourla asserted that meaningful advances in U.S. immunization policy hinge on a “change in leadership at the top” of the Department of Health and Human Services. Without naming individuals, he specified the office of Health Secretary as the locus of needed reform, arguing that fresh direction is essential to restore scientific rigor and credibility to vaccine programs. Investors may view this as a signal that ongoing policy uncertainty could affect federal funding priorities and regulatory timelines for Pfizer’s vaccine pipeline.

Bourla cautioned that underinvestment in U.S. universities has ceded scientific leadership to China, where reforms in intellectual property protections and regulatory modernization have accelerated pharmaceutical innovation. He noted that Chinese institutions now occupy roughly 80 percent of top-tier positions in health research rankings, and that domestic drugmakers are shifting from generics to novel therapies. For investors, this trend underscores intensifying competition in both early-stage research and commercial markets, and suggests that Pfizer’s growth trajectory may increasingly depend on strategic alliances, M&A and expanded R&D investment to counter China’s “meteoric rise.”